2216 Stock Overview
A medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Broncus Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.49 |
| 52 Week High | HK$0.90 |
| 52 Week Low | HK$0.46 |
| Beta | 0.91 |
| 11 Month Change | -5.77% |
| 3 Month Change | -10.91% |
| 1 Year Change | -44.94% |
| 33 Year Change | -95.19% |
| 5 Year Change | n/a |
| Change since IPO | -96.73% |
Recent News & Updates
Recent updates
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully
Mar 21
Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans
Nov 30Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?
May 31Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth
Feb 27An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued
Dec 06Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers
Sep 04Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation
Jun 21Shareholder Returns
| 2216 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 5.4% | -2.4% | -2.8% |
| 1Y | -44.9% | -38.5% | 10.0% |
Return vs Industry: 2216 underperformed the Hong Kong Medical Equipment industry which returned -38.5% over the past year.
Return vs Market: 2216 underperformed the Hong Kong Market which returned 10% over the past year.
Price Volatility
| 2216 volatility | |
|---|---|
| 2216 Average Weekly Movement | 12.1% |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2216 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2216's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 208 | Hong Xu | www.broncus.com |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); RF-II, transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Ablation System for the treatment of COPD; H-Marker, treatment for lung cancer/lung nodules; disposable nebulizing micro-catheter for endoscope used for accurate anti-inflammation, local hemostasis, phlegm reduction and elimination, staining location, and local anesthesia; and BroncTru, a disposable transbronchoscopic puncture dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPoint ATV System, an archimedes system.
Broncus Holding Corporation Fundamentals Summary
| 2216 fundamental statistics | |
|---|---|
| Market cap | HK$242.51m |
| Earnings (TTM) | -HK$165.78m |
| Revenue (TTM) | HK$67.90m |
3.8x
P/S Ratio-1.6x
P/E RatioIs 2216 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2216 income statement (TTM) | |
|---|---|
| Revenue | US$8.73m |
| Cost of Revenue | US$2.57m |
| Gross Profit | US$6.16m |
| Other Expenses | US$27.46m |
| Earnings | -US$21.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 70.54% |
| Net Profit Margin | -244.16% |
| Debt/Equity Ratio | 0.008% |
How did 2216 perform over the long term?
See historical performance and comparison